Bacitracin is a polypeptide antibiotic produced by certain strains of Bacillus licheniforrnis. It inhibits bacterial cell wall synthesis and induces the accumulation in Staphylococcus aureus of UDP-acetylmuramyl-pentapeptide,I a precursor of the cell wall. Recent studies of the detailed mechanism of biosynthesis of the peptidoglycan of bacterial cell walls have revealed a process that occurs in three stages, viz.: (1) biosynthesis of the uridine nucleotide precursors, (2) utilization of these precursors to form linear peptidoglycanl strands, and (3) cross-linlking of the linear strands.2 Each of these stages is specifically inhibited by different antibiotics. Ristocetin, vancomycin, and bacitracin are all inhibitors of the second stage.I This stage is a complex reaction sequence which occurs in the cell membrane as a consequence of which the sugar fragments of the uridine nucleotide precursors become attached to a phospholipid carrier in the membrane and are then modified. Studies of the individual reactions in this cycle (Fig. 1) 
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action in which the modified disaccharide-pentapeptide units are transferred from the lipid carrier to an endogenous acceptor is the reaction most sensitive to ristocetin and vancomycin.4 5 However, the mode of action of bacitracin has not been clear. On the one hand, isotopic experiments supported the hypothesis that its site of inhibition preceded the cross-linking reaction.6 On the other hand, inhibition of peptidoglycan synthesis in Micrococcus lysodeikticus by bacitracin re-BIOCHEMISTRY: SIEWERT AND STROAIINGER PROC. N. A. S. quired a higher concentration than that required to inhibit the growth of cells.3' 4 When the over-all reaction of peptidoglycan synthesis from the uridine nucleotide precursors was investigated, the synthesis of peptidoglycan was only partially inhibited by bacitracin to an extent varying between 25 and 80 per cent.4 Complete inhibition could never be obtained, and in some experiments no inhibition at all was observed. Moreover, when individual steps of the reaction cycle were investigated, none of those studied was found to be sensitive to bacitracin. 7 These observations suggested that bacitracin might be an inhibitor in a portion of the reaction cycle which had not been directly investigated, namely, either the reaction sequence which led to the de novo synthesis of lipid-P, the lipid carrier in the reaction sequence, or the reaction in which the presumed intermediate, lipidwas dephosphorylated to regenerate lipid-P. A compound with properties suggesting that it was lipid-P-P was isolated in trace amounts from P32-labeled cells of Al. lysodeikticus, but the amount obtained was insufficientt to permit characterization. 8 In the present study, it will be shown that bacitracin is a specific inhibitor of the dephosphorylation of lipid-P-P. This latter substance accumulated after inhibition of the reaction cycle with bacitracin, thus establishing its role as an intermediate.
Materials and Methods.-General procedures and substrates employed have been described in a recent publication.4 After isolation of lipid-P-P32 (labeled only in the terminal phosphate, see below), a convenient assay for the phosphatase was developed as follows: Incubation mixtures contained 6 Results.-Lipid content and enzymatic activity in particulate enzyme prepared from cells pretreated with bacitracin: If the effects of bacitracin were due to reducing the supply of lipid-P to the reaction cycle, either by inhibition of its de novo synthesis or by inhibition of the hypothetical lipid-P-P phosphatase, then the lipid-P content of particulate enzyme from cells pretreated with this antibiotic should be lowered while enzymatic activity was normal. The amount of lipid-P present in cells pretreated with 150 Ag/ml bacitracin was only 37 per cent of the control value (measured by the amount of disaccharide-C 14-pentapeptide which could be attached to the endogenous carrier) (Fig. 2) . When a crude lipid extract was added back to these particles, however, activity in the particles from bacitracin-treated cells was stimulated to a greater extent than that in the untreated cells, so that both types of preparations attained the same maximum activity. This experiment indicated that the amount of enzyme protein in the treated cells was relatively normal while their content of lipid-P was diminished.
Utilization of disaccharide (C14-pentapeptide)-P32-P-lipid for peptidoglycan syn- (Fig. 3 ). This material did not contain any detectable C14 and is assumed to be lipid-P-P32. It had similar chromatographic mobilities to the material which had previously been isolated in trace amount from P32-labeled cells.8
Similar results were obtained when disaccharide (C14-pentapeptide)-P32-P-lipid was prepared using particulate enzyme from S. aureus and employed as a substrate with enzyme from this organism, i.e., bacitracin inhibited release of inorganic phosphate without inhibiting peptidoglycan synthesis (Table 1) . By contrast with either Al. lysodeikticus or S. aureus particulate enzyme, ristocetin inhibited both formation of C14-peptidoglycan and liberation of P32 inorganic phosphate ( Fig. 3 and Table 1 ) and did not result in accumulation of lipid-P-P32.
The effects of b-qcitracin on the complete reaction cycle: The whole reaction cycle can be studied wvith P32-UDP-acetylmuramyl-Ci4-pentapeptide as the substrate. At a low concentration of this substrate, the system employing particulate enzyme from Al. lysodeikticus was not saturated, and the rate of peptidoglyean synthesis was relatively low. Under these conditions bacitracin had no effect on Ci4-peptidoglycan synthesis, inhibited the release of P32-inorganic phosphate from the precursor, and induced accumulation of lipid-P-P32 (Table 2) lysodeiktic (180 pig of protein) in a total volume of 30 pl. After 1 hr incubation at 370, the reactions were stopped by heating the tubes in a boiling water bath for 1 min. The mixtures were spotted on Whatman no. 3 MM filter paper and chromatographed in isobutyric acid: 1 N NH40H (5:3) as described previously.3. 4. The spots of C14-peptidoglycan, inorganic-P32, and lipid-P-P32 were located by radioautography (Fig.  3) and were counted in a Packard Tri-Carb liquid scintillation spectrometer. nucleotide substrate was increased approximately fivefold, the reaction velocity was considerably enhanced. Under these conditions peptidoglycan synthesis was inhibited by bacitracin in addition to its other effects (Table 2 ). This inhibition occurs because under these conditions lipid-P recycles in the absence of bacitracin, and its regeneration from lipid-P-P, which is blocked by bacitracin, is required for the recycling. The number of cycles in which the lipid carrier has participated is thus the ratio of the amount of peptidoglycan synthesis in the control to that formed in the presence of bacitracin or the ratio of the amount of inorganic phosphate released in the control to the amount of lipid-P-P accumulated in After 1 hr of incubation at room temperature, C'4-peptidoglycan and inorganic-P32 were measured as described in Fig. 4 . The reaction mixtures contained p32, C'"-UDP-Mur-NAc-pentapeptide (0.82 mamole for low substrate concentration containing 52,000 cpm of p32 and 61,000 cpm of C14; 4.1 mjamoles for high substrate concentration containing 40,000 cpm of p32 and 51,500 cpm of C14), UDP-GlcNAc (5 and 15 mpamoles, respectively), 3 pAmoles of Tris-H1C, pH 8.6, 1 jumole of MgCl2, 0.02 jamole of 2-mercaptoethanol and particulate enzyme from M. lysodeikticus (120 pg of protein) in a total volume of 28 pl. After incubation for 1 hr at 370, assay of C14 peptidoglycan, inorganic p32 and lipid-P-P'2 formation was carried out as described in Fig. 4. observed, while under conditions where recycling occurs, bacitracin inhibits peptidoglycan synthesis, the extent of inhibition depending upon the number of reaction cycles which have occurred.
Isolation of lipid-P-P32 and the effects of bacitracin on its dephosphorylation: Lipid-P-P32 from M. lysodeikticus was accumulated in a large-scale experiment similar to that of Table 2 , extracted from the reaction mixture with n-butanol:6 Al pyridinium acetate, pH 4.2, and purified on a column of silicic acid employing a gradient of methanol in chloroform. Deoxycholate (0.16%) was required for utilization of this purified lipid-P-P32 by the particulate enzyme from M. lysodeikticus, a requirement which had previously been observed in studies of the utilization of lipid-P for formation of disaccharide (-pentapeptide)-P-P-lipid.8 Lipid-P-P32 was rapidly dephosphorylated under these conditions, and the dephosphorylation was inhibited by bacitracin (Fig. 5) . The concentration for 50 per cent inhibition was approximately 4 ,ug/ml of bacitracin. A similar value (8 gg/ml) can also be calculated from the data of Figure 4 in which the lipid intermediate was employed as substrate. The dephosphorylation of lipid-P-P32 employing the particulate enzyme from S. aureus was inhibited 50 per cent by about 6 ;Lg/ml of bacitracin. Employing the lipid intermediate from S. aureus as substrate, a value of about 5 /Ag/ml was obtained. It is of some interest to comparative biochemistry that lipid-P-P32 isolated from Ml. lysodeikticus could be dephosphorylated by particulate enzyme from both organisms. Bacitracin was the only one of the specific inhibitors of bacterial cell wall synthesis which inhibited the dephosphorylation of lipid-P-P32. Penicillin, ristocetin, vancomycin, and novobiocin had no effect on this reaction (Table 3) . Dephosphorylation of lipid-P-P32 by other phosphatases: Both Escherichia coli alkaline phosphomonoesterase (Fig. 5 ) and alkaline phosphatase from calf intestinal mucosa catalyzed the dephosphorylation of this substrate (although the specific activities were very low), and in both cases the dephosphorylation was inhibited by bacitracin. The acid phosphatases from potatoes and from wheat germ catalyzed dephosphorylation of lipid-P-P32 at a very slow rate, if at all. The amount of bacitracin required for 50 per cent inhibition of dephosphorylation by E. coli phosphomonoesterase, approximately 6 Ag/ml, was similar to that required for inhibition of dephosphorylation by the particulate enzyme. Bacitracin at a very high concentration (200 ,g/ml) had no effect at all on the hydrolysis of glucose 1-P or p-nitrophenyl-P by the E. coli enzyme. The concentration required to inhibit the dephosphorylation of lipid-P-P was virtually identical to the growth-inhibitory concentration in the case of M. lysodeikticus and much lower than the growth-inhibitory concentration in the case of S. aureus. These experiments thus suggest that inhibition of the dephosphorylation of lipid-P-P is the specific locus of action of bacitracin in inhibiting cell growth. In the case of S. aureus it would appear that the enzyme is more sensitive than are the intact cells, a phenomenon which suggests that the relatively low sensitivity of cells of S. aureus to this antibiotic may be due to its inability to penetrate to the site of this enzyme in the bacterial cell. The isolation of lipid-IP-P phosphatase, its char-772 VOL. 57, 1967 BIOCHEMISTRY: SIEWERT AND STROMINGER acterization, and the study of the precise mechanism of inhibition of this enzyme by bacitracin remain as important problems. It is not yet clear whether the inhibition of the system is due to the interaction of the antibiotic with the lipid substrate or with the phosphatase."2 It is possible that the toxicity of bacitracin for the kidney of higher animals is due to its interaction either with a related lipid in kidney membranes or with a phosphatase in which the kidney is known to be rich. Summary. -Bacitracin inhibits bacterial cell wall synthesis and induces an accumulation of UDP-acetylmuramyl-pentapeptide in growing cells of S. aureus. With particulate enzymes which catalyze peptidoglyean synthesis, in the presence of bacitracin disaccharide (-pentapeptide)-P-P-lipid, an intermediate in cell wall synthesis, was utilized to form peptidoglyean without the liberation of inorganic phosphate. A lipid, assumed to be lipid-P-P, accumulated. This compound was isolated and its dephosphorylation was shown to be specifically inhibited by bacitracin. Bacitracin, therefore, inhibits peptidoglycan synthesis by preventing the lipid carrier from re-entering the reaction cycle of cell wall synthesis.
